These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17455356)

  • 1. Efficient co-crystal screening using solution-mediated phase transformation.
    Zhang GG; Henry RF; Borchardt TB; Lou X
    J Pharm Sci; 2007 May; 96(5):990-5. PubMed ID: 17455356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
    Almarsson O; Zaworotko MJ
    Chem Commun (Camb); 2004 Sep; (17):1889-96. PubMed ID: 15340589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solubility prediction, solvate and cocrystal screening as tools for rational crystal engineering.
    Loschen C; Klamt A
    J Pharm Pharmacol; 2015 Jun; 67(6):803-11. PubMed ID: 25851032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability.
    Greco K; Bogner R
    J Pharm Sci; 2012 Sep; 101(9):2996-3018. PubMed ID: 22213419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical considerations for the qualitative and quantitative determination of process-induced disorder in crystalline solids.
    Newman A; Zografi G
    J Pharm Sci; 2014 Sep; 103(9):2595-2604. PubMed ID: 24623166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms.
    Kawakami K; Usui T; Hattori M
    J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing pseudopolymorphic transitions in pharmaceutical solids using Raman spectroscopy: hydration and dehydration of theophylline.
    Amado AM; Nolasco MM; Ribeiro-Claro PJ
    J Pharm Sci; 2007 May; 96(5):1366-79. PubMed ID: 17455358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of co-crystals in pharmaceutical design.
    Steed JW
    Trends Pharmacol Sci; 2013 Mar; 34(3):185-93. PubMed ID: 23347591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deliquescence of pharmaceutical systems.
    Mauer LJ; Taylor LS
    Pharm Dev Technol; 2010 Dec; 15(6):582-94. PubMed ID: 19895256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desolvation kinetics of sulfameter solvates.
    Khawam A; Flanagan DR
    J Pharm Sci; 2008 Jun; 97(6):2160-75. PubMed ID: 17975809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of hydrate-screening methods.
    Cui Y; Yao E
    J Pharm Sci; 2008 Jul; 97(7):2730-44. PubMed ID: 17914731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding.
    Karki S; Friscić T; Jones W; Motherwell WD
    Mol Pharm; 2007; 4(3):347-54. PubMed ID: 17497885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid state amorphization of pharmaceuticals.
    Willart JF; Descamps M
    Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical co-crystals-an opportunity for drug product enhancement.
    Miroshnyk I; Mirza S; Sandler N
    Expert Opin Drug Deliv; 2009 Apr; 6(4):333-41. PubMed ID: 19348603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of the causes of cocrystal dissociation at high humidity.
    Eddleston MD; Thakuria R; Aldous BJ; Jones W
    J Pharm Sci; 2014 Sep; 103(9):2859-2864. PubMed ID: 24481664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of solid-state NMR to pharmaceutical polymorphism and related matters.
    Harris RK
    J Pharm Pharmacol; 2007 Feb; 59(2):225-39. PubMed ID: 17270076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of mid-IR spectroscopy for the characterization of pharmaceutical systems.
    Van Eerdenbrugh B; Taylor LS
    Int J Pharm; 2011 Sep; 417(1-2):3-16. PubMed ID: 21167267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.